IMVT-1402 missed its primary endpoint in cutaneous lupus erythematosus, and Immunovant is dropping the indication. The proof-of-concept trial failed to show statistically significant improvement on CLASI-A score at week 12, the standard measure of skin disease activity, and the company announced it will not advance the program further in CLE.
The miss matters beyond one indication. IMVT-1402 (imeroprubart) is an FcRn inhibitor designed to reduce circulating IgG autoantibodies by blocking the receptor that recycles them back into the bloodstream. The logic for CLE was straightforward: IgG autoantibodies drive skin damage in lupus, so depleting them should reduce disease activity. That the drug did not move the needle on CLASI-A suggests either that IgG-mediated pathology is less central to CLE activity than the mechanism implies, or that the patient population or trial design did not give the biology a fair test. Immunovant has not disclosed which interpretation it accepts.
The broader FcRn class remains active. Johnson and Johnson’s nipocalimab received FDA approval in April 2025 for generalized myasthenia gravis, a condition where IgG autoantibodies are the direct disease driver. CLE pathophysiology is messier: T-cell-mediated inflammation, UV-triggered keratinocyte damage, and interface dermatitis all contribute alongside autoantibody activity, which may explain why IgG clearance alone produced an insufficient signal. Approved treatment options for CLE remain limited, largely managed with antimalarials and off-label immunosuppressants, so the unmet need is real. The failure here does not answer whether a different FcRn inhibitor or a longer trial would produce a different result.
Immunovant’s other IMVT-1402 programs are unaffected by this readout. The indicator to watch is whether the company discloses any subgroup signal from the CLE data, particularly in patients with measurably elevated baseline IgG, which would clarify whether the mechanism was simply mismatched to the indication or whether the molecule itself underperformed.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
